<DOC>
	<DOCNO>NCT00313092</DOCNO>
	<brief_summary>The aim study determine plasma matrix-metalloproteinase activity predict glaucoma patient OSAS level plasma matrix-metalloproteinase activity decrease one month nCPAP-treatment .</brief_summary>
	<brief_title>Obstructive Sleep Apnea Syndrome Glaucoma</brief_title>
	<detailed_description>Glaucoma lead cause blindness world-wide . Chronic primary open-angle glaucoma common form among Caucasian patient . The key feature glaucoma damage optic nerve head , necessarily relate increase intraocular pressure . The prevalence glaucoma among patient sleep apnoea 7,2 % : normal-tension glaucoma 2,9 % , primary open-angle glaucoma 4,3 % . The prevalence obstructive sleep apnoea syndrome ( OSAS ) around 4-10 % men 2-4 % woman . Matrix metalloproteinases ( MMPs ) substrates include essentially extracellular matrix component well wide array molecule involve intracellular adhesion , cell-matrix interaction , cell signalling . However , MMPs effect restrict extracellular matrix degradation . The prevalence increase MMP patient OSAS predict value additional glaucoma know . Further , know treatment OSAS nasal continuous positive air pressure ( nCPAP ) decrease MMP activity . With study , want determine prevalence MMP activity prevalence glaucoma patient OSAS . Further , want investigate nCPAP treatment period four week decrease MMP activity .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>OSAS plan begin nCPAP treatment Current malignancy Oral steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>OSAS</keyword>
	<keyword>glaucoma</keyword>
	<keyword>MMP</keyword>
</DOC>